What is the recommended treatment and management for angina pectoris?

Management of Angina Pectoris

All patients with angina pectoris must receive aspirin 75-100 mg daily and a statin for cardiovascular event prevention, combined with beta-blockers as first-line antianginal therapy, titrated to maximum tolerated dose before adding other agents. 1, 2

Immediate Symptom Relief

• Sublingual nitroglycerin is mandatory for acute angina episodes and should be taken prophylactically before activities known to trigger symptoms 1, 2
• If sublingual preparations fail, switch to buccal glyceryl trinitrate formulations 1

Disease-Modifying Therapy (Mortality & Morbidity Reduction)

Every patient requires this triple combination:

• Aspirin 75-100 mg daily (or clopidogrel 75 mg if aspirin intolerant) 1, 2
• Statin therapy for LDL-cholesterol reduction regardless of baseline levels 1, 2
• ACE inhibitor for all patients to reduce cardiovascular events 2

First-Line Antianginal Therapy

Beta-blockers are the cornerstone of antianginal treatment and provide the strongest mortality benefit, particularly in patients with prior myocardial infarction 1, 2

• Selective β₁-blockers are preferred: bisoprolol, metoprolol succinate, or nebivolol 2
• Titrate to maximum tolerated dose before adding any second agent 2
• Never stop abruptly—taper over 4 weeks to prevent rebound ischemia 1, 2
• Absolute contraindication: asthma; use caution (not contraindicated) in COPD and peripheral vascular disease 2

Second-Line Therapy Algorithm

If symptoms persist despite optimized beta-blocker monotherapy:

Add ONE of the following:

1. Dihydropyridine calcium channel blocker (amlodipine)—preferred second agent 1, 2

   • Safe in heart failure and effective for both angina and hypertension 2
   • Short-acting dihydropyridines must never be used without concurrent beta-blocker coverage 2

2. Long-acting nitrates (if amlodipine not tolerated) 1, 2

   • Mandatory 8-12 hour nitrate-free interval to prevent tolerance 1, 2
   • Minimum effective patch dose ≥10 mg 1, 2
   • Contraindicated with phosphodiesterase-5 inhibitors and in hypertrophic cardiomyopathy 1, 2

3. Ivabradine (only if patient in sinus rhythm) 1, 2

   • Not recommended if LVEF >40% without clinical heart failure 1, 2
   • Never combine with non-dihydropyridine CCBs or strong CYP3A4 inhibitors 1, 2

Alternative Second-Line Options When Beta-Blockers Contraindicated:

• Non-dihydropyridine CCBs (verapamil or diltiazem) 1, 2
  • Avoid in systolic dysfunction, sick sinus syndrome, or high-grade AV block 2
  • Never combine with beta-blockers (risk of excessive bradycardia/AV block) 2

Third-Line Therapy

If symptoms persist on two optimized agents, consider:

• Ranolazine—particularly effective in microvascular angina and patients with low heart rate or blood pressure 2
• Nicorandil (potassium-channel activator) 2
• Trimetazidine (metabolic agent for low heart rate/blood pressure patients) 2

However, evidence for triple therapy is limited; referral for revascularization should be strongly considered at this stage 1, 2

Critical Drug Interaction Warnings

• Never combine: ivabradine + non-dihydropyridine CCB 1, 2
• Never combine: nitrates + phosphodiesterase-5 inhibitors 1, 2
• Never combine: beta-blocker + non-dihydropyridine CCB 2

Lifestyle Modifications (Mandatory for All Patients)

• Smoking cessation is non-negotiable—advise all smokers to stop; nicotine patches can be used safely but only as part of a broader strategy 1
• Aerobic exercise 150-300 minutes/week moderate intensity or 75-150 minutes/week vigorous intensity 1
• Multidisciplinary exercise-based cardiac rehabilitation program reduces cardiovascular mortality 1
• Weight reduction to normal BMI for overweight patients 1
• Blood pressure control according to published guidelines 1
• Cholesterol measurement and management for all patients 1

Referral Indications

Refer to cardiology for:

• All patients with clinically certain angina to identify those requiring prognostic investigation 1
• Uncertain diagnosis requiring clarification 1
• Uncontrolled symptoms despite full doses of two drugs—refer for angiography, not exercise testing 1
• Patients not adequately controlled by two drugs should be referred rather than given a third drug 1

Special Population Considerations

Vasospastic Angina:

• High-dose CCBs are first-line (verapamil up to 480 mg/day, diltiazem up to 260 mg/day, nifedipine up to 120 mg/day) 2
• Beta-blockers may worsen spasm—avoid 2
• Add long-acting nitrates if CCB monotherapy insufficient 2

Heart Failure with Angina:

• Beta-blocker is mandatory first-line, reducing both HF hospitalizations and mortality 2
• If intolerant: ivabradine, long-acting nitrates, or amlodipine 2
• Avoid non-dihydropyridine CCBs in reduced ejection fraction 2

Microvascular Angina:

• Ranolazine or trimetazidine particularly effective 2
• Combine with beta-blocker + ACE-inhibitor + statin 2

Common Pitfalls to Avoid

• Inadequate beta-blocker dose titration before adding second agents is the most frequent error 2
• Continuous nitrate exposure without 8-12 hour drug-free interval causes tolerance 1, 2
• Abrupt beta-blocker discontinuation triggers rebound ischemia 1, 2
• Using short-acting dihydropyridines without beta-blocker coverage increases adverse cardiac events 2
• Prescribing ivabradine to patients with LVEF >40% without heart failure 1, 2

Compliance and Cost Considerations

• Within any drug class, use the cheapest preparation the patient can tolerate that controls symptoms 1
• Ensure patients understand their medication regimen and monitor for side effects 1
• Warn patients never to allow beta-blockers to run out 1